Robotic surgery fuels Johnson & Johnson dividend growth outlook

J&J announced plans to separate its Orthopaedics business into a standalone company called DePuy Synthes. The move will be completed within 18 to 24 months."Our surgical technologies are used in most operating rooms globally. And in Q3, we delivered more than 9% growth in biosurgery and almost 7% in wound closure, driven by accelerating adoption of our latest innovations," Schmid said.Tim Schmid, Executive Vice President of MedTech at J&J, emphasized the company's commitment during the recent earnings call ...